Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells

Cancer chemotherapy is fraught with systematic toxicities due to the non-specificity of anti-cancer drugs. Mamot et al design immunoliposomes that target epidermal growth factor receptor and its truncated variant EGFRvIII, and evaluate their potential in providing intracellular drug delivery in canc...

Full description

Saved in:
Bibliographic Details
Published inThe women's oncology review Vol. 4; no. 2; pp. 99 - 101
Main Authors Krishnada, Aparna, Onyuksel, Hayat
Format Journal Article
LanguageEnglish
Published Boca Raton Taylor & Francis Ltd 01.06.2004
Subjects
Cancer
Cells
Clinical trials
Drug therapy
Oncology
Tumors
Online AccessGet full text

Cover

More Information
Summary:Cancer chemotherapy is fraught with systematic toxicities due to the non-specificity of anti-cancer drugs. Mamot et al design immunoliposomes that target epidermal growth factor receptor and its truncated variant EGFRvIII, and evaluate their potential in providing intracellular drug delivery in cancer cells expressing these receptors.
ISSN:1473-3404
DOI:10.1080/14733400410001727592